在心脏再同步治疗中生存益处的患者特异性修饰剂 - - 一个多中心相互作用分析
Bert Vandenberk1,2, Marius Brusselmans3, Gabor Voros1,2
1Department of Cardiology, UZ Leuven, Leuven, Belgium.
ESC heart failure
|July 30, 2025
概括
与除器 (CRT-D) 的心脏再同步治疗相比,与起器 (CRT-P) 相比,显著降低了死亡率. 关键的患者因素,如LBBB形态,喷射率和功能影响CRT-D的好处.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 临床试验 临床试验
背景情况:
- 心脏再同步治疗 (CRT) 对于心力衰竭管理至关重要.
- 使用除器 (CRT-D) 进行CRT和使用心脏起器 (CRT-P) 进行CRT之间的选择取决于患者的具体情况.
- 这项研究调查了临床变量如何改变CRT-D与CRT-P对死亡率的益处.
研究的目的:
- 分析临床特征对CRT患者全因死亡率的影响.
- 确定特定患者因素如何影响CRT-D与CRT-P的比较有效性.
- 确定从CRT-D获得最大生存益处的患者子组.
主要方法:
- 来自三个欧洲中心的2271名接受CRT植入的患者的回顾性分析.
- 利用多变量Cox比例危险模型与相互作用测试来评估死亡率.
- 研究了临床变量之间的相互作用以及CRT-D和CRT-P之间的选择.
主要成果:
- 与CRT-P (HR 0.65) 相比,CRT-D显示所有原因死亡率减少了35%.
- 确定了左束枝块 (LBBB) 形态,左心室喷射率 (LVEF) 和功能方面的显著相互作用.
- 在LBBB,特定的LVEF范围和充分的功能患者中,CRT-D的益处最为明显.
结论:
- 左捆分支块形态,LVEF和功能是CRT-D对CRT-P益处的关键预测因素.
- 这些因素有助于为接受CRT的患者个性化治疗决策.
- 植入式心脏转换器-除器治疗组件CRT-D在选择的心力衰竭患者中提供了生存优势.
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
01:22Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
01:30Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
01:30Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
52
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
52
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510